ENALARE THERAPEUTICS INC

Princeton, NJ · Founded 2018 · Biotech · Private

ENA-001, a novel chemical entity small molecule therapeutic for opioid overdose and respiratory conditions

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · enalare.com

Sector: Biotech
Headquarters: Princeton, NJ
Founded: 2018
Latest Form D: $12.5M, Aug 2022
Total capital: $29.6M

Federal grants: $3.1M; 3 awards · 2022–2025; Rank in peer group#451 of 502
Private capital raised: $13.5M; 3 Form D · last Aug 2022; 50 months since last filing
Federal contracts: $13M; 2 awards · Health and Human S; Rank in Biotech#53 of 4373
Granted patents: 2; 24 pending · first 2024; Rank in peer group#41 of 502

Capital timeline

Latest events

Jan 2025Federal grantHealth and Human S · Phase II · Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.$2.5M
Sep 2022Federal contractHealth and Human S · Enalare Therapeutics: An Agnostic Respiratory Stimulant For Use As A Medical Countermeasure To Treat Respiratory Depression$12.2M
Aug 2022Private capital raisedForm D · SEC · 3rd filing$12.5M
Jul 2022Federal grantHealth and Human S · Phase I · Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.$320K
Jun 2022Federal grantHealth and Human S · Phase II · Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.$320K
Feb 2022Private capital raisedForm D · SEC · 2nd filing$1M
Apr 2021Federal contractHealth and Human S · Enalare Therapeautics, Inc.: Repurposing Drugs In Response To Chemical Threats (redirect) ENA-001$749K
Dec 2020Offering registeredForm D · SEC · 1st filing$5M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

Federal grantsBelow median
Granted patents#41 · top 8%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Joseph PergolizziResearcherExecutive Officer, DirectorLinked by 1 patent · $320K in grants as PI
Daniel MottoExecutive OfficerNamed in SEC Form D filings
Gino SantiniDirectorNamed in SEC Form D filings
Herman CukierExecutive Officer, DirectorNamed in SEC Form D filings
Joseph PetkoDirectorNamed in SEC Form D filings
Mark ColemanDirectorNamed in SEC Form D filings

Show all 7 people

Robert YedidDirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 26

Sep 1, 2026GrantedLarge-conductance Potassium Channel Modulators, Compositions Thereof, Methods Of Manufacturing Thereof, And Methods Of Use ThereofUSPTOUS 12,721,850
May 21, 2026PendingMethods And Pharmaceutical Compositions To Treat Drug OverdoseUSPTOApplication 19446156
Oct 23, 2025PendingMethods And Pharmaceutical Compositions To Treat Respiratory Depression In PatientsUSPTOApplication 18866742

Show all 26 patent records

Large-conductance Potassium Channel Modulators, Compositions Thereof, Methods Of Manufacturing Thereof, And Methods Of Use ThereofSep 1, 2026 · US 12,721,850Granted
Methods And Pharmaceutical Compositions To Treat Drug OverdoseMay 21, 2026 · Application 19446156Pending
Methods And Pharmaceutical Compositions To Treat Respiratory Depression In PatientsOct 23, 2025 · Application 18866742Pending
Methods And Compositions For Treating Drug OverdoseApr 10, 2025 · Application 18909393Pending
Methods Of Treating Respiratory Depression Modulated By A Non-opioid AgentJan 30, 2025 · Application 18795777Pending
Methods Of Treating Respiratory Depression Modulated By A Non-opioid AgentNov 12, 2024 · US 12,138,267Granted
Large-conductance Potassium Channel Modulators, Compositions Thereof, Methods Of Manufacturing Thereof, And Methods Of Use ThereofJul 18, 2024 · Application 18289288Pending
Methods Of Treating Neurological Ventilatory InsufficiencyDec 28, 2023 · Application 18213451Pending
Respiratory Stimulant Nasal FormulationsOct 5, 2023 · Application 18129538Pending
Respiratory Stimulant Parenteral FormulationsJul 6, 2023 · Application 18088137Pending
Respiratory Stimulant Nasal FormulationsApplication PCTUS2023017126Pending
Respiratory Stimulant Parenteral FormulationsApplication PCTUS2022053935Pending
Methods And Compositions For Treating Drug OverdoseApplication 63615566Pending
Methods Of Treating Respiratory Depression Modulated By A Non-opioid AgentApplication PCTUS2022048669Pending
Methods Of Treating Neurological Ventilatory InsufficiencyApplication 63355255Pending
Methods and Pharmaceutical Compositions to Treat Respiratory Depression in PatientsApplication 63343744Pending
Large-conductance Potassium Channel Modulators, Compositions Thereof, Methods Of Manufacturing Thereof, And Methods Of Use ThereofApplication PCTUS2022027637Pending
Respiratory Stimulant Nasal FormulationsApplication 63326578Pending
Respiratory Stimulant Parenteral FormulationsApplication 63313472Pending
Respiratory Stimulant Parenteral FormulationsApplication 63293985Pending
Methods Of Treating Respiratory Depression Moduated By A Non-opioid AgentApplication 63274722Pending
Large-conductance Potassium Channel Modulators, Compositions Thereof, Methods Of Manufacturing Thereof, And Methods Of Use ThereofApplication 63183717Pending
Methods And Compositions For Treating Drug OverdoseApplication PCTUS2024050346Pending
Methods And Compositions For Treating Drug OverdoseApplication 63543177Pending
Methods Of Treating Neurological Ventilatory InsufficiencyApplication PCTUS2023026078Pending
Methods And Pharmaceutical Compositions To Treat Respiratory Depression In PatientsApplication PCTUS2023022705Pending

BLUEWILLOW BIOLOGICS INCSimilar federal contract value in Biotech · $14.7M in contracts
VitriVaxSimilar federal contract value in Biotech · $14.5M in contracts
HDT BIO CORPSimilar federal contract value in Biotech · $14.5M in contracts
INIMMUNE CORPSimilar federal contract value in Biotech · $12.8M in contracts
ZATA PHARMACEUTICALS, INC.Similar federal contract value in Biotech · $12.6M in contracts
INOVIO PHARMACEUTICALS, INC.Similar federal contract value in Biotech · $12M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.